Abstract
Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Current Psychopharmacology
Title:Antipsychotics Management in Addictive Disorders
Volume: 2
Author(s): Pierre Alexis Geoffroy, Benjamin Rolland, Vincent Laprevote and Olivier Cottencin
Affiliation:
Keywords: Antipsychotics, addiction, comorbidity, impulsivity, reward system, substance use disorder.
Abstract: Several authors have hypothesized that antipsychotics could down-regulate the activation of dopamine receptors in the mesolimbic pathway, thus decreasing the occurrence and the intensity of addiction-related symptoms. We conducted a critical review of the theoretical arguments that have been published on this subject and evaluated how they compare to the published clinical data. Despite interesting findings, the effects of antipsychotics may not be as compelling as what would be theoretically expected. Thus far, antipsychotics have shown no efficacy in treating addictive disorders alone. Nevertheless, effective strategies for the use of antipsychotics against addictions are available and discussed. To treat individual vulnerability factors to addictions, such as psychiatric comorbidities (schizophrenia or bipolar disorder) that share vulnerability factors with addictive disorders and contribute to triggering addictive behaviors are among the strategies. The evidence for using antipsychotics is still the best in subjects with comorbid schizophrenia and alcohol or substance use disorder. Additionally, in some clinical situations of major impulsivity, the off-label prescription of atypical antipsychotics is worth exploring, but should be further investigated in a clinical setting.
Export Options
About this article
Cite this article as:
Geoffroy Alexis Pierre, Rolland Benjamin, Laprevote Vincent and Cottencin Olivier, Antipsychotics Management in Addictive Disorders, Current Psychopharmacology 2013; 2 (3) . https://dx.doi.org/10.2174/221155601130200006
DOI https://dx.doi.org/10.2174/221155601130200006 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Cardioprotection with opioids - Trusted old friends -Clinical Science -
Current Pharmaceutical Design A Clinician’s Guide to Monoamine Oxidase Inhibitors
Current Psychiatry Reviews Graphical Abstracts:
Central Nervous System Agents in Medicinal Chemistry Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry Withdrawn: Alkaloidal Content, Medicinal, Properties of Peganum harmala L. (P. harmala)
Current Traditional Medicine Fabrication, Characterization, In vitro Evaluation of Solid Lipid Nanoemulsion of Flunarizine dihydrochloride for Nasal Delivery
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Discovery of CDP323, a Potent Alpha4 Integrin Antagonist
Current Immunology Reviews (Discontinued) Editorial: Multitarget Molecules for Alzheimer's Disease Therapy
Current Topics in Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression
Current Neuropharmacology Planum Temporale Analysis Via a New Volumetric Method in Autoptic Brains of Demented and Psychotic Patients
Current Alzheimer Research Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research The Wnt Pathway in Mood Disorders
Current Neuropharmacology